Handa Pharmaceuticals, Inc.

Money Moves

As of September 2026: Developer of OMCAZIO

The FDA cleared a Taiwanese drugmaker to sell an alternate-salt version of the $2.1 billion cancer drug cabozantinib in the United States. The final approval lands three days after a federal appeals court kept generic entry shut by upholding patents on the originator's salt form.

Updated Sep 11